GE HealthCare Receives CE Mark for Revolutionary Total Body PET/CT System and Digital SPECT/CT Platform
核心洞察
GE HealthCare announced CE Mark approval for its Omni 128cm total body PET/CT system, designed to advance cancer diagnosis and treatment monitoring with head-to-thigh imaging in a single bed position.
The company also received CE Mark for its StarGuide GX digital 4D SPECT/CT system, featuring dual-sided CZT detector technology capable of imaging alpha emitters and all energy levels for nuclear medicine applications.
Both systems leverage NVIDIA (搜索) accelerated computing technology to optimize image reconstruction and reduce scan times, supporting the growing demand for theranostics and precision medicine.
GE HealthCare announced CE Mark approval for two groundbreaking molecular imaging systems that promise to transform cancer diagnosis and nuclear medicine applications. The Omni 128cm total body PET/CT system and StarGuide GX digital 4D SPECT/CT platform represent significant advances in precision imaging technology, addressing the growing global cancer burden projected to increase 77% by 2050.
Revolutionary Total Body PET/CT Technology
The Omni 128cm total body PET/CT system enables head-to-thigh imaging in a single bed position for a wide range of patients, compared to traditional systems requiring five-to-six bed positions. This capability significantly accelerates scan times and streamlines workflows while supporting ultra-low dose scans and multi-organ dynamic imaging.
"Our commitment to precision health is rooted in innovation that also aims to anticipate the future of care," said Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. "With our Omni 128cm total body PET/CT system, we're not just advancing imaging – we're building a platform that empowers clinicians to deliver personalized, efficient and impactful care."
The system's ultra-high sensitivity and excellent spatial resolution support imaging across diverse clinical applications, including advanced prostate cancer treatment monitoring. Its non-invasive nature and ability to quantify biological processes at the cellular level make it valuable for early disease identification and treatment planning.
Prof. Michael Hofman, nuclear medicine physician and head of the PET/CT program at Melbourne's Peter MacCallum Cancer Centre (搜索), emphasized the technology's potential: "With the Omni 128cm total body PET/CT system, we're entering a new phase of possibility – one where faster scans and broader imaging coverage could redefine how we approach translational research and accelerate the development of targeted therapies."
Advanced Digital SPECT/CT Platform
The StarGuide GX system features dual-sided CZT detector technology designed to deliver ultra-high sensitivity and high-resolution imaging for fast, confident diagnostics. The system's patented dual collimator detector design eliminates the need for traditional manual or automated external exchanges, streamlining workflows and reducing physical strain on operators.
StarGuide GX represents an all-in-one system capable of imaging virtually all energy levels for general-purpose SPECT imaging, including the acquisition of investigational alpha therapies such as Actinium-225 (搜索). This versatility optimizes the platform for exploring emerging therapeutic applications.
"StarGuide GX is an innovation sure to prove valuable now and in the future," said Erez Levy, executive director, Molecular Imaging, GE HealthCare. "Its ability to image alpha emitters and deliver accurate quantitation in short scan times could create new opportunities for clinicians to personalize treatment with great confidence."
Clinical Impact and Efficiency
Both systems leverage NVIDIA (搜索) accelerated computing technology to optimize reconstruction processes and reduce image generation times. The Omni 128cm system includes intuitive artificial intelligence solutions to promote clinical and operational efficiency, while StarGuide GX enables fast scans and precise dynamic imaging.
Ken Herrmann, MD, director and chair, Department of Nuclear Medicine, Universitätsklinikum Essen, highlighted the clinical significance: "This next-generation PET/CT technology is engineered to deliver exceptional sensitivity and resolution – capabilities that could reshape how we approach molecular imaging. Its speed and precision open the door to new possibilities, from helping reduce the need for anesthesia in pediatric scans to enabling multi organ dynamic imaging and early, confident diagnoses."
Supporting Theranostics and Research
The growing prevalence of cancer and emergence of investigational immunotherapies and targeted treatments have accelerated demand for whole-body PET/CT imaging. Both systems support theranostics applications and enable researchers to develop new clinical pathways and evaluate emerging therapeutic agents.
The Omni 128cm system supports advanced research applications from developing novel PET tracers to evaluating theranostic agents, accelerating innovation from bench to bedside. When combined with GE HealthCare's MIM software solutions, researchers and clinicians gain access to advanced quantitation tools and streamlined workflows.
StarGuide GX features a lead-free laser-printed collimator that supports global sustainability goals while contributing to impressive image quality. The system is designed to help departments manage growing patient volumes with limited resources through reduced workload and efficient workflows.
Industry Milestone
The CE Mark approvals mark significant milestones for GE HealthCare, which celebrates 25 years of PET/CT innovation in 2025. From launching the industry's first commercially available PET/CT system, Discovery LS, to introducing these next-generation solutions, the company continues delivering innovative technologies to meet current and future healthcare needs.